<?xml version="1.0" encoding="UTF-8"?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="JATS-archive-oasis-article1-4.xsd" article-type="research-article" dtd-version="1.4" xml:lang="ru">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Журнал Современные проблемы науки и образования</journal-title>
      </journal-title-group>
      <issn>2070-7428</issn>
      <publisher>
        <publisher-name>Общество с ограниченной ответственностью "Издательский Дом "Академия Естествознания"</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">ART-10405</article-id>
      <title-group>
        <article-title>МАРКЕРЫ СОСТОЯНИЯ ПОЧЕЧНЫХ ФУНКЦИЙ У БОЛЬНЫХ С КАРДИАЛЬНОЙ ПАТОЛОГИЕЙ</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name-alternatives>
            <name xml:lang="ru">
              <surname>Волков</surname>
              <given-names>А.С.</given-names>
            </name>
          </name-alternatives>
          <name-alternatives>
            <name xml:lang="en">
              <surname>Volkov</surname>
              <given-names>A.S.</given-names>
            </name>
          </name-alternatives>
          <email>ronikia@gmail.com</email>
          <xref ref-type="aff" rid="aff5b267b9b"/>
        </contrib>
        <contrib contrib-type="author">
          <name-alternatives>
            <name xml:lang="ru">
              <surname>Нестеренко</surname>
              <given-names>О.В.</given-names>
            </name>
          </name-alternatives>
          <name-alternatives>
            <name xml:lang="en">
              <surname>Nesterenko</surname>
              <given-names>O.V.</given-names>
            </name>
          </name-alternatives>
          <email>ronikia@gmail.com</email>
          <xref ref-type="aff" rid="aff5b267b9b"/>
        </contrib>
        <contrib contrib-type="author">
          <name-alternatives>
            <name xml:lang="ru">
              <surname>Шевченко</surname>
              <given-names>О.В.</given-names>
            </name>
          </name-alternatives>
          <name-alternatives>
            <name xml:lang="en">
              <surname>Shevchenko</surname>
              <given-names>O.V.</given-names>
            </name>
          </name-alternatives>
          <email>shevchenkoov@inbox.ru</email>
          <xref ref-type="aff" rid="aff5b267b9b"/>
        </contrib>
        <contrib contrib-type="author">
          <name-alternatives>
            <name xml:lang="ru">
              <surname>Протопопов</surname>
              <given-names>А.А.</given-names>
            </name>
          </name-alternatives>
          <name-alternatives>
            <name xml:lang="en">
              <surname>Protopopov</surname>
              <given-names>A.A.</given-names>
            </name>
          </name-alternatives>
          <email>ronikia@gmail.com</email>
          <xref ref-type="aff" rid="aff5b267b9b"/>
        </contrib>
        <contrib contrib-type="author">
          <name-alternatives>
            <name xml:lang="ru">
              <surname>Бородулин</surname>
              <given-names>В.Б.</given-names>
            </name>
          </name-alternatives>
          <name-alternatives>
            <name xml:lang="en">
              <surname>Borodulin</surname>
              <given-names>V.B.</given-names>
            </name>
          </name-alternatives>
          <email>borodulinvb@mail.ru</email>
          <xref ref-type="aff" rid="aff5b267b9b"/>
        </contrib>
      </contrib-group>
      <aff id="aff5b267b9b">
        <institution xml:lang="ru">ГОУ ВПО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава России</institution>
        <institution xml:lang="en">Saratov State Medical University n. a. V. I. Rasumovsky</institution>
      </aff>
      <pub-date date-type="pub" iso-8601-date="2013-05-21">
        <day>21</day>
        <month>05</month>
        <year>2013</year>
      </pub-date>
      <issue>5</issue>
      <fpage>331</fpage>
      <lpage>331</lpage>
      <permissions>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the CC BY 4.0 license.</license-p>
        </license>
      </permissions>
      <self-uri content-type="url" hreflang="ru">https://science-education.ru/ru/article/view?id=10405</self-uri>
      <abstract xml:lang="ru" lang-variant="original" lang-source="author">
        <p>Представлен обзор современной научной литературы, посвященной изучению состояния почек при кардиальной патологии. Дано представление о кардиоренальном континууме как о непрерывной цепи изменений от факторов риска (АГ, СД и др.) до развития терминальной ХПН и гибели больного. Согласно рекомендациям NKF (NationalKidneyFoundation) скорость клубочковой фильтрации (СКФ) является лучшим универсальным показателем уровня фильтрационной функции почек.Однако при определении СКФ традиционным способом по креатинину возникают проблемы, связанные с недостаточной точностью такого способа. По сравнению с креатинином повышение цисС происходит более быстро в диапазоне СКФ от 70 до 40 мл/мин/1,73м2. Уровень сывороточного цисС коррелирует с тяжестью ССЗ и АГ, а рСКФцисС может применяться в качестве более чувствительного метода, чем клиренс креатинина, для прогнозирования микроальбуминурии (МАУ) и гиперфильтрации.</p>
      </abstract>
      <abstract xml:lang="en" lang-variant="translation" lang-source="translator">
        <p>The review of the current scientific literature on the study of the state of the kidneys in cardiac pathology. Given the understanding of the cardiorenal continuum as a continuous chain of changes of risk factors (hypertension, diabetes , etc. ) to the development of terminal renal failure and death of the patient. According to the recommendations of the NKF (National Kidney Foundation) glomerular filtration rate (GFR) is the best indicator of a universal filtration function of the kidney. However, when determining GFR conventional manner creatinine problems associated with insufficient accuracy of this method. Compared with creatinine increase CysC occurs more rapidly in the range of GFR of 70 to 40 mL/min/1 73m2. Serum levels correlate with the severity of CysC CVD and hypertension, and rSKFCysC can be used as a more sensitive method than the creatinine clearance for the prediction of microalbuminuria (MAU) and reverse osmosis.</p>
      </abstract>
      <kwd-group xml:lang="ru">
        <kwd>цистатин С.</kwd>
        <kwd>креатинин</kwd>
        <kwd>хроническая болезнь почек</kwd>
      </kwd-group>
      <kwd-group xml:lang="en">
        <kwd>cystatin C</kwd>
        <kwd>creatinine</kwd>
        <kwd>chronic kidney disease</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <ref>
        <note>
          <p>1.	Есаян А.М. Эссенциальная гипертензия с нефропатией. Насколько это актуально в наши дни?// Нефрология.  – 2008. – Т. 12. – №2. – С.22-25.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>2.	Мухин Н.А., Моисеев B.C., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек // Терапевтический архив. – 2004.–№ 6. – С. 39-46.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>3.	Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии// Нефрология. – 2005. –Т. 9. –№3. –С. 7-15.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>4.	Anavekar N.S., Pfeffer M.A. Cardiovascular risk in chronic kidney disease// Kidney Int. – 2004. –№ 66. – Р.1-15.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>5.	Azevedo M.J., Gross J.L. Follow-up of glomerular hyperfiltration in normoalbuminuric type 1 (insulin-dependent) diabetic patients//Diabetologia. – 1991. – № 34.–Р. 611-614.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>6.	Chiarelli F, Verrotti A, Morgese G. Glomerular hyperfiltration increases the risk of developing microalbuminuria in diabetic children//PediatrNephrol. – 1995. – Vol.9(154).–Р.8-11.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>7.	Conti M., Moutereau S., Zater M. et al. Urinary cystatin C as a specific marker of tubular dysfunction // Clin. Chem. Lab. Med. — 2006. — Vol. 44 (3). — P. 288–291.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>8.	Go A., Cherow G., Fan D., Mc.Culloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death and cardiovascular events and hospitalization// N Engl J Med. – 2004. – № 351.– Р. 1296–1305.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>9.	Jones S.L., Wiseman M.J., Viberti G.C. Glomerular hyperfiltration as a risk factor for diabetic nephropathy: five-year report of a prospective study//Diabetologia. – 1991. –№34. –Р.59–60.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>10.	Kanno A., Kikuya M., Ohkubo T., Hashimoto T. et al.Pre-hypertension as a significant predictor of chronic kidney disease in a general population: the Ohasama//Study. Nephrol Dial Transplant.–2012. – № 27(8). –Р. 218-23.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>11.	Lervang H.H., Jensen S., Brochner-MortensenJ., et al. Early glomerular hyperfiltration and the development of late nephropathy in type 1 (insulin-dependent) diabetes mellitus//Diabetologia.– 1988. –№ 31. –Р.723–729.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>12.	Lipsey M., Furebring M., Rubertsson S., Larsson A. Significant differences when using creatinine, modification of diet in renal disease, or cystatin C for estimating glomerular filtration rate in ICU patients//Upsala J.   Med Sci.– 2011. – № 116. – Р. 39–46.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>13.	Maahs D.M., Jalal D., McFann K, et al. Systematic shifts in cystatin C between 2006 and 2010//Clin J Am SocNephrol. – 2011. –№ 6. – Р.1952–1955.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>14.	Mogensen C.E. Early glomerular hyperfiltration in insulindependent diabetics and late nephropathy//Scand J Clin Lab Invest. – 1986. – №46. – Р.201–206.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>15.	Okada R., Yasuda Y., Tsushita K. et al. Glomerular hyperfiltration in prediabetes and prehypertension//Nephrol Dial Transplant.– 2012. –Vol.27(5). – Р. 1821-1825.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>16.	Peralta C.A., Katz R., Sarnak M.J., Ix J.H., Fried L.F.et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications// J Am SocNephrol. – 2011. – № 22. – Р. 147-155.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>17.	Peralta C.A., Shlipak M.G., Judd S et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality// JAMA. – 2011. –Vol.305(15). – Р. 1545-1552.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>18.	Rosolowsky E.T., Niewczas M.A., Ficociello L.H., Perkins B.A.et al.  Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy// Diabetes Res ClinPract.– 2008. – № 82 (suppl. 1). –Р.46-53.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>19.	Rudberg S., Persson B., Dahlquist G., Increased glomerular filtration rate as a predictor of diabetic nephropathy – an 8-year prospective study// Kidney Int. – 1992. –№41. –Р.822–828.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>20.	White C.A., Rule A.D., Collier C.P. et al. The impact of interlaboratory differences in cystatin C assay measurement on glomerular filtration rate estimation//Clin J Am SocNephrol. – 2011. –№6. –Р.2150–2156.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>21.	 Yip J.W., Jones S.L., Wiseman M.J. et al. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study// Diabetes.– 1996. –№45. –Р.1729–1733.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>22.	Zerbini G., Bonfanti R., Meschi F. et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes// Diabetes. – 2006. –№55. –Р.2620–2625.</p>
        </note>
      </ref>
      <ref>
        <note>
          <p>23.	Zahran A., El-Husseini A., Shoker A.   Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review//Am J Nephrol.– 2007.– Vol.27(2).– Р.197-205.</p>
        </note>
      </ref>
    </ref-list>
  </back>
</article>
